



Figure e-2. **Increase in frequency of CXCR3-expressing B cells in peripheral blood under natalizumab.** Frequencies of cells with the phenotype CD3⁻, CD19⁺, CD45RA⁺, HLA-DR⁺, CXCR3⁺ in PBMC from blood taken before or after the start of treatment with natalizumab were assessed by fluorescence flow cytometry in longitudinal blood samples from 7 patients with MS and expressed as a percentage of total lymphocytes defined by light scatter (** p = 0.0075, paired, two-tailed t test).